Oncotelic Unveils Four-Gene HCC Signature for Sapu003 Trials
Oncotelic said a peer-reviewed study identified a four-gene prognostic signature using its PDAOAI platform, validated in a 203-patient Japanese cohort, to stratify patients for Sapu003 clinical development.